BioCentury
ARTICLE | Company News

Noven, Hisamitsu Pharmaceutical Co. Inc. deal

August 24, 2009 7:00 AM UTC

Hisamitsu completed its initial tender offer for Noven, acquiring about 21.9 million shares (87.4%) at $16.50, or about $362 million. The figure includes about 340,000 shares delivered through notices...